that require parenteral administration. Therapy choices for CP 690,550 from the treatment of RA could contain co administration with MTX, here we report the results of a Phase I, open label study of the pharmacokinetics of numerous doses of CP 690,550 and single doses of oral MTX in RA patients. This study was performed in preparation for conducting a Phase IIb study in RA patients on a background of steady MTX dosing. This study was carried out from the USA. The study was sponsored by Pzer Inc. and was carried Ivacaftor out in compliance with all the ethical principles originating in, or derived from, the Declaration of Helsinki, and in compliance with all Worldwide Conference of Harmonization
and an estimated glomerular ltration rate 60 ml min1. Patients were to continue taking stable background RA therapy, including nonsteroidal anti inammatory drugs, cyclooxygenase 2 inhibitors and low dose oral corticosteroids. Other prescription or nonprescription medication, vitamins and dietary supplements were for being stopped inside 14 days prior to the rst dose of trial medication and throughout the course of the trial. The pharmacodynamic effects of MTX are long lived,consequently it was neither ethical nor feasible to require patients to wash out MTX till their RA ared. Consequently, the study was created to let wash out of MTX based JNJ 1661010 on typical MTX PK before evaluating the PK of CP 690,550. Patients were conned to the clinical research unit from day
size of at least 12 patients allowed for calculation of the probable 90% condence intervals that could be expected for various possible relative exposure estimates of AUC and Cmax for CP 690,550 in the presence and absence of MTX, and for MTX in the presence and absence of CP 690,550. These calculations were based on estimates of within subject standard deviations of 0. 31 and NSCLC 0. 28 for loge AUC and loge Cmax, respectively, for CP 690,550, as obtained from a previous study of CP 690,550. It was also assumed that estimates of within subject standard
Thursday, March 21, 2013
Ivacaftor JNJ 1661010 Untruths You've Been Advised About
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment